Clinical Trial

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-09-17; most recent amendment 2025-09-19.
Status change: Not Yet Recruiting → Recruiting 2021-11-02
Trial Details
NCT Number NCT04561206
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Relapsed Classic Hodgkin Lymphoma
Enrollment 31 participants
Start Date 2021-11-12
Primary Completion 2026-10-02 (estimated)
Study Completion 2026-10-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-24